Thromb Haemost 1996; 75(02): 246-250
DOI: 10.1055/s-0038-1650253
Original Article
Schattauer GmbH Stuttgart

A Fixed-Dose Combination of Low Molecular Weight Heparin with Dihydroergotamine versus Adjusted-Dose Unfractionated Heparin in the Prevention of Deep-Vein Thrombosis after Total Hip Replacement

T Horbach
1   The Surgical Clinic and Out-Patient Department, University of Erlangen, Germany
,
H Wolf
2   Medical Department, Sandoz AG, Nuremberg, Germany
,
H C Michaells
2   Medical Department, Sandoz AG, Nuremberg, Germany
,
W Wagner
1   The Surgical Clinic and Out-Patient Department, University of Erlangen, Germany
,
A Hoffmann
1   The Surgical Clinic and Out-Patient Department, University of Erlangen, Germany
,
A Schmidt
3   The institute for Clinical Research, Hamburg, Germany
,
H Beck
1   The Surgical Clinic and Out-Patient Department, University of Erlangen, Germany
› Author Affiliations
Further Information

Publication History

Received: 14 September 1995

Accepted after resubmission10 November 1988

Publication Date:
26 July 2018 (online)

Summary

The low dose heparin regimen (LDH) is not appropriate for prevention of intra- and postoperative thromboembolic complications in high risk patients, especially those undergoing elective hip replacement. Despite LDH prophylaxis, the incidence of deep-vein thrombosis (DVT) remains in a range of 20 to 35%. Adjusted-dose unfractionated heparin prophylaxis is thought to be one of the most effective regimens for thrombosis prophylaxis in this indication, but it requires two or three daily injections as well as precise monitoring of the activated partial thromboplastin time (aPTT). As an attractive alternative, we investigated the efficacy and safety of the low molecular weight heparin (LMWH) certoparin combined with dihydroergotamine (DHE) given once daily.

In a randomised, open clinical trial, a total number of 305 patients undergoing total elective hip replacement were enrolled and divided into two groups, either receiving a fixed-dose combination of LMWH (3,000 IU) and DHE (0.5 mg) subcutaneously once daily, or adjusted-dose unfractionated heparin (UFH) subcutaneously every 8 h. The UFH dosage was adjusted daily to keep an aPTT of about 50 s. The aPTT was determined 3 h after the morning injection. During the study, the starting dose (15,000 IU/day) was increased to a plateau value of 28,800 ± 7,150 IU/day (mean ± SD) to maintain the aPTT in the prescribed range. The plateau value was achieved after 8 postoperative days. For analysis of efficacy 289 patients were evaluable. The occurrence of deep vein thrombosis was determined by bilateral ascending venography, which was performed on the same day in patients with clinical signs suggesting DVT; and in all remaining patients at the end of the prophylaxis period. Deep vein thrombosis was diagnosed in 17 of 142 patients (12.0%) treated with LMWH/DHE and in 13 of 147 patients (8.8%) treated with adjusted-dose UFH. Combined distal-proximal thrombosis was more frequently in patients receiving UFH (n = 5; 3.4%) compared to the LMWH/DHE group (n = 2; 1.4%). These differences are statistically not significant. In the UFH group one case of non-fatal pulmonary embolism occurred. Both prophylaxis regimens were well tolerated; wound bleeding was observed in 8 (5.3%) patients in the LMWH group and in 6 (4.0%) patients in the UFH group. Intraoperative blood-loss volume (mean±SD) was 751 ± 339 ml (LMWH/DHE) and 736 ± 380 ml (UFH), whereas postoperative drain-loss volume (mean ± SD) was found to be 523 ± 333 ml (LMWH/DHE) and 581 ± 404 ml (UFH). Whole blood transfusion volumes (mean ± SD) were 570 ± 202 ml (LMWH/DHE) and 748 ± 455 ml (UFH). Additionally, red cell replacement volumes (mean ± SD) were 804 ± 435 ml (LMWH/DHE) and 720 ± 328 ml (UHF). Revision of wound or additional drainage were necessary in 3 LMWH/DHE and 7 UFH patients. One patient needed reoperation due to bleeding, 3 (2.0%) had petechia and 1 exhibited an allergic exanthema, all of them in the UFH group. A slight erythema at the injection site was observed in 6 (3.9%) patients receiving LMWH/DHE. During the course of prophylaxis, injection hematomas were documented in 57.9% (LMWH/DHE) and in 61.4% (UFH) of the patients. All differences were statistically not significant.

Single daily subcutaneous injections of LMWH/DHE appeared to be safe and efficacious compared to adjusted-dose UFH for prophylaxis of DVT in high-risk patients.

 
  • References

  • 1 Consensus Conference. Prevention of Venous Thrombosis and Pulmonary Embolism. JAMA 1986 256. 744-748
  • 2 Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore PI, Neviaser RJ, Rubin BE, Varma VM. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg (AM) 1978; 60: 1065-1070
  • 3 Sagar S, Stamatakis JD, Higgins AF, Naim D, Maffei FH, Thomas DP, Kakkar VV. Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total hip replacement. Lancet 1976; 1: 1151-1154
  • 4 Gent M, Roberts RS. A meta-analysis of the studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis. Chest 1986; 89: 396-400
  • 5 Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, Candardjis G. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983; 308: 954-957
  • 6 Tabemer DA, Poller L, Thomson JM, Lemon G, Weighill FJ. Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg 1989; 76: 933-935
  • 7 Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-920
  • 8 Nurmohamed MT, Rosendaal FR, Biiller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156
  • 9 Kakkar VV, Stringer MD, Hedges AR, Parker CJ, Welzel D, Ward VP, Sanderson RM, Cooper D, Kakkar S. Fixed combinations of low-molecular weight of unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. A J Surg 1989; 157: 413-418
  • 10 Sasahara AA, Koppenhagen K, Häring R, Welzel D, Wolf H. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein, thrombosis. Br J Surg 1986; 73: 697-700
  • 11 Voth D, Schwarz M, Hahn K, Dei-Anang K, Butmeh S, Wolf H. Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimens. Neurosurg Rev 1992; 15: 289-294
  • 12 Freick H, Haas S. Prevention of deep vein thrombosis by low-molecular-weight heparin and dihydroergotamine in patients undergoing total hip replacement. Thromb Res 1991; 63: 133-143
  • 13 Haas S, Stemberger A, Fritsche HM, Welzel D, Wolf H, Lechner F, Blümel G. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneim.-Forsch/Drug Res 1987; 37: 839-843
  • 14 Wolf H, Welzel D, Kaiser H, Majer M, Schäfer D, Husfeldt KJ, Voigt J, Sunder-Plassmann L. Bewertung der perioperativen Thromboembolie-Prophylaxe mit niedermolekularem Heparin und Dihydroergotamin. Arzneim.-Forsch./Drug Res 1988; 38: 1516-1519
  • 15 Weber U, Koppenhagen K, Malzer H, Matthes M. Unterschiedliche Wirksamkeit von zwei Praparaten mit niedermolekularem Heparin bei Patienten mit elektivem Htiftgelenksersatz. Langenbecks Arch Chir 1991; 376: 147-151